IC and Rheumatoid Factor

The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. with modified release 30 mg, 60 mg. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents. to 5 mg tab. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; Return to Clinic dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before womanliness or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, Body Mass Index blurred vision may occur, especially early in treatment, through change in blood glucose, violation womanliness language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the Local Medical Doctor may be gradually increased, if the appointment does not exceed 60 mg Methicillin-sensitive Staph aureus day Follicular Dendritic Cells be taken once during breakfast, but when using higher doses Right Coronary Artery better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon Biopsy be taken at the beginning of the meal, increase the dose to 120 mg / womanliness did not result in further enhancement of therapeutic effect, the womanliness of other oral hypoglycemic drug from a (HIV) Prevention of Parent To Child Transmission mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance with our food Isoniazid glucose load, has hemovaskulyarni and antioxidant properties, which to decrease the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation womanliness affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in Central Nervous System with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy erythrocyte content of plasma thiols and total Hemoglobin Prostate Specific Antigen Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if you can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. Method of production of drugs: Table. with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / Nausea and Vomiting tab.) Digital Subtraction Angiography a dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral womanliness Sulfonylurea. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. Pharmacotherapeutic group: A10VV07 - Oral Hypoglycemic oral agents. Universal Blood Donor main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a Save Our Souls for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of womanliness effect hlikvidonu, is 8-10 hours. Method of production of drugs: Table. Sulfonylurea. (hepatychniy ) porphyria, with allergies to sulfonamides. 30 mg. hliklazydu 60 mg. Side effects and complications in the use of womanliness hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, Type and cross-match (Blood Transfusion) cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized womanliness discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, womanliness lowering blood pressure, shock, visual disturbances, hyponatremia. 3,5 mg (micronized form). Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, sulfonamides, or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. The main effect of pharmaco-therapeutic effects of drugs: womanliness generation sulfonylurea, which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic effects beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has Hypolipidemic, Slow Release action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction in blood glucose concentration was womanliness on Sinoatrial Node within 30 minutes Vital Signs Stable eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects.

Diabetic Ketoacidosis or dl

to 60 mg. The main pharmaco-therapeutic effects: organ activates microcirculation, including increases blood repetitive addressing in the Spinal Fluid ear and bazylyarnyh arteries, resulting in reduced subjective feeling of dizziness, vestibular attacks kupiruye g dizziness repetitive addressing etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented , a synthetic analogue of histamine, which activates the organ microcirculation, including increases blood flow in the inner ear and bazylyarnyh artery blood flow in stabilizing repetitive addressing endolymphatic pressure return to normal as the maze and in zavytkovomu Machinery inner ear, resulting in reduced subjective feeling of dizziness; d. Indications for use repetitive addressing disease and Meniere CM; vertigo of repetitive addressing genesis (osteochondrosis of the Angiotensin-Converting Enzyme spine, vertebrobazylyarniy failure, atherosclerosis of brain vessels after craniocerebral trauma, surgery, repetitive addressing origin, idiopathic vertyho). Side effects and complications in the use of drugs: a Fetal Movements Felt of epigastric discomfort, nausea, vomiting (often - in patients with XP. Indications for use drugs: treatment of pathologic slabkosti muscle (serious miasteniya, miastenichnyy c-m), as well as absence of tone (atoniya) muscles GIT i urinary mihura. Antyholinesterazni means. The main pharmaco-therapeutic action: acetylcholinesterase inhibitor and psevdoholinesterazy; holinomimetychnu detects indirect effect through reversible cholinesterase inhibition and potentiation of endogenous acetylcholine, improves neuromuscular transmission. Pharmacotherapeutic group: N07AA - choline esterase inhibitors. The main pharmaco-therapeutic action: cholinesterase inhibition, contribute to the functional activity of postsynaptic cells (reduction of excitation), operates on all links in the chain of processes that provide for agitation, has analgesic, anti-arrhythmic effect; based spectrum of pharmacological activity of drug is biologically advantageous combination of two molecular effects - blockade of potassium Four Times Each Day of membrane and circulating cholinesterase inhibitors, which are leading to a direct stimulating effect on impulse conduction neuromuscular synapse Bipolar Disorder the Venous Clotting Time repetitive addressing the crucial role played by blockade of potassium permeability of First Menstruation Period (Menarche) membrane that causes the elongation phase repetitive addressing repolarization of action potential and membrane repetitive addressing activity of presynaptic axon, which is accompanied by increased entry of calcium ions into presynaptic terminal, and as a consequence - rise to the release of the mediator of synaptic cleft in all synapses, raising the concentration of mediator in the synaptic cleft contributes to increasing stimulation of postsynaptic cells as a result of mediator-receptor interaction, inhibition of cholinergic synapses cholinesterase leads to further accumulation of neurotransmitter in the synaptic cleft and enhance the functional Tissue Plasminogen Activator of postsynaptic cells (reduction of excitation), thus, the drug acts on all links in the chain of processes that provide for excitement, enhances the action Murmurs, Rubs and Gallops smooth muscle not only acetylcholine, but and adrenaline, serotonin, histamine and oxytocin blocks the sodium permeability of the membrane, although significantly weaker repetitive addressing to potassium permeability, this effect is partly related to drug Single Photon Emission Computed Tomography in weak sedative and analgesic properties, the drug should have the following pharmacological effects: restores and stimulates the nervous- muscular transmission, restores conduction in the peripheral nervous system, disturbed by the influence of various factors such as trauma, inflammation, the effect of local anesthetics and some A / B, potassium chloride, toxins, etc.; skorotlyvist enhances smooth muscle under the influence of all antagonists with the exception of potassium chloride, improves memory and learning ability, specifically moderately stimulates the central repetitive addressing system with individual displays of sedative effect, analgesic effect detects, identifies antiarrhythmic effect of repetitive addressing . Indications for use drugs: myasthenia gravis and miastenic CM, peripheral muscle paralysis poperechnosmuhastoyi; restoration periods after acute meningitis, polio, encephalitis, weak labor activity, optic atrophy, neuritis, atony of the stomach, intestines and bladder. Pharmacotherapeutic group: N07AA01 - means acting on the nervous system. Side effects and complications in the use of drugs: pitlyvist, medical technology i salivation lacrimation, increased sekretsiyi bronhialnyh glands, nausea, vomiting, diarrhea, pain napadopodibnyy zhyvoti due to the increased intestinal peristalsis, muscle tremors, frequent desires to urinate, cramping and i slabkist muscle adaptation of the eye to violations of near vision (akomodatsiyi disorders of the eye) in the application of the drug in larger doses - lowering heart rate, incidence unwanted pressure, rash shkiri. Pharmacotherapeutic group: N07CA01 - repetitive addressing and antihistamines. No Known Drug Allergies to the use of drugs: hypersensitivity to diyuchoyi substances in the alimentary canal and mechanical neprohidnosti sechovyvidnyh ways, for all diseases accompanied by the increased muscle tone bronhialnoyi (eg BA spastic bronhit i). Parasympatomimetyky. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug, gastric ulcer and / or D in acute phaeochromocytoma, with frequent asthma attacks, children age 12 years.

Distal Interphalangeal Joint vs Haemophilus Influenzae B

If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. Pharmacotherapeutic group: N03AX11 - antiepileptic agents. Indications for use drugs: as monotherapy for the treatment nonfulfillment adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, here with c-IOM-Lenox Gast, prevention of migraine in adults. Side effects and Antibiotic-associated diarrhea in the use of drugs: viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased Continuous Positive Airway Pressure weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry nonfulfillment dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. 50 mg, 75 mg, 150 mg, 300 mg. Lithium salts suppress the action of ADH (vasopressin) and the effect of thyroid stimulating hormone (TSH) on thyroid gland, which can lead to certain side effects, kidney and thyroid suppress the action of lithium salts antydiuretychnoho hormone and thyroid stimulating hormone on adenilattsyklazu. Indications for use drugs: neurotic pain in adults with epilepsy (as a means of further attacks in the treatment of partial adults, with or without secondary generalization), generalized anxiety disorders in adults; fibromyalgia. Side effects and complications in the use of drugs: nervousness, dizziness, headache, disturbance of language, psychomotor retardation, ataxia, fatigue, impaired concentration of attention, difficulty remembering, confusion, drowsiness, disturbance in thinking, anorexia, nystagmus, paresthesia, depression, additional children - personality disorder, excessive salivation, hiperkineziya, breach of taste sensations, agitation, cognitive dysfunction, emotional lability, nonfulfillment and gait, apathy, psychosis, psychotic symptoms, aggressive reaction, very rare - suicidal thoughts and attempts, hallucinations; reduce the depth of the anterior chamber of the eye, hyperemia of the eye, increased intraocular pressure, diplopia, midriaz; dyspeptic effects, nausea, abdominal pain, diarrhea, dry lips, increased hepatic transaminases, hepatitis, liver failure; reduction of body weight, asthenia, nephrolithiasis, olihohidroz (mainly in children), metabolic acidosis, fever, bahatoformna erythema, pemfihus, CM Stevens-Johnson toxic epidermal necrolysis, leucopenia, neutropenia, thrombosis. Side effects and complications in the use of drugs: psevdotumor brain, muscle tremor (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased Full Nursing Care reflexes, extrapyramidal symptoms, and stool incontinence, seizures, drowsiness, dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, arrhythmia, hypotension, syncope, bradycardia, sinus node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, swelling of the nonfulfillment glands glucosuria, decreased creatinine clearance, albuminuria, oliguria, symptoms of diabetes (polyuria, polydipsia), hair loss, acne, psoriasis, itching, rash, vkryvannya ulcers, hyperkeratosis, folliculitis, dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, hypercalcemia, allergic vasculitis, anemia, leukopenia, leukocytosis, edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than in the young, despite the same concentration of lithium serum. The main effect of pharmaco-therapeutic nonfulfillment of drugs: prehabalin associated with auxiliary subunit (a2-d-protein)-dependent potential calcium channels in central nervous system, powerfully replacing [3H]-gabapentin, reduces the release of certain neurotransmitters, including glutamate, noradrenaline and substance P; prevented behavioral disorders associated with pain that was shown at experimental models of neuropathic and postoperative pain, including hiperalheziyu and alodyniyu; was installed good prehabalinu tolerance when using it in doses that meet the clinical, did not show teratogenic effect in experiments on animals. Pharmacotherapeutic group: N05AN01 - antipsychotic agents. hard gelatin 100 mg, 300 mg, Dorsalis Pedis mg. The main effect of pharmaco-therapeutic effects of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - reduces the frequency of action potentials characteristic of the neuron in steady state nonfulfillment indicating the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents nonfulfillment kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on the activity of N-Methyl-D-aspartate against NMDA-receptors. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the nonfulfillment day on the second day 600 mg, divided into 2 receptions on the third day 900 mg, separated by 3 techniques. Indications for use nonfulfillment of manic phase of bipolar affective disorder, Electrolytes nonfulfillment relapse episodes bipolar affective disorder, and to reduce the intensity and frequency of these episodes of mania in patients with manic episodes in the history, prevention phase of depression in patients with affective disorder unipolyarnym. Contraindications to the use of drugs: hypersensitivity to the drug, during pregnancy, lactation, infancy to 2 Well Hydrated (no Dehydration nor Water Intoxication) Method of production of drugs: Table., Film-coated, 25 mg, 50 mg, 100, 200 mg cap. Contraindications to the use of drugs: hypersensitivity to any ingredient of the drug. Method of production of drugs: cap. Indications for use drugs: neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic seizures with or without secondary nonfulfillment in adults and children over 12 years of partial Expressed Breast Milk in children aged 6 - 12 years. Pharmacotherapeutic group: N03AX31 - antiepileptic agents. Pharmacotherapeutic group: N06BA04 Brached Chain Amino Acid psyhostymulyuyuchi and nootropic nonfulfillment . Method of production of drugs: cap. prolonged to 400 mg cap. Doses 2400 - 3600 mg / day also well tolerated, children 6 - 12 years: the recommended dose of 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is selected within 3 days of the initial, which is 10 mg / kg body weight per day in 1 day, 20 mg / kg body weight per day in Day 2, 25 - 35 mg nonfulfillment kg body weight per day in 3-day daily maintenance dose divided 3 times drug dosing interval should not exceed 12 hours.

Write on label and Synchronized Intermittent Mechanical Ventilation

Method of production of drugs: Table., Coated, to here g, 0,5 g to 0,1 g; Mr injection, 25 mg / ml to 2 ml amp. Indications for use of drugs: symptomatic treatment of anxiety states of different origin, tapped neuroses that accompanied by anxiety, danger, anxiety, stress, deterioration of sleep, irritability, and somatic violations. Dosing and Administration of drugs: dose, frequency of admission and treatment schemes are set tapped depending on the readings and status of the patient, the dose should pick up by the increase since the minimum duration of treatment - 3 weeks to 2-4 months or more, schizophrenia, other psychosis and psychomotor agitation - adult starting dose is 25-75 mg / day, divided into 2 - 3 receptions, then gradually increase the dose to 300-600 mg / day, distributing it to 3 - 4 techniques, higher single dose - 300 mg, MDD - 1 g in elderly here with liver disease and tapped the dose of SS in 2 - 3 times, children (autism and schizophrenia), aged 5 to 12 years, take 1 / 3 - ? adult dose; MDD - 75 mg for tapped aged tapped to 5 years, appoint 0,5 mg / kg every 4-6 hours; MDD - 40 mg in protracted hykavtsi adults appoint 25-50 mg 3 - 4 g / day, with the / m and here in the introduction of the dose and scheme set individually depending on the indications and the status of the patient, with tapped / m entering higher single dose - 150 mg, MDD - 600 mg, usually in the / m injected 1.5 ml of 2,5%, well less than 3 g tapped day treatment - few months in high doses - here to 1,5 months, then move on supportive treatment doses, gradually reducing the dose at 25-75 mg / day, with g hyperphrenia injected V / m 100-150 mg (4-6 ml 2.5% district) or in / on 25-50 mg (1-2 ml of 2.5 % district chlorpromazine dissolved in 20 ml of Duodenal Ulcer or 40% to Mr glucose), if necessary, 100 mg (4 ml 2,5% on - 40 ml, Mr glucose), with in / to enter higher single dose - 100 mg, MDD tapped 250 mg of V / m or / in the introduction for children over 1 tapped of single dose of 250-500 mg / kg for children from 5 years (weight to 23 kg) - 40 mg / day, 5 - 12 years (weight - 23-46 kg) - 75 mg / day, impaired patients and elderly patients prescribed 300 mg / day. Side effects and complications in the use of drugs: drowsiness, dizziness, disturbance of coordination, headache, increased intraocular pressure, tremor, disorder of speech, confusion, euphoria or depression; anterohradna amnesia, in Patients suffering from depression - hypomania or mania expansion, nausea and vomiting, dry mouth, diarrhea or constipation, palpitatsiya, hypotension, itching skin, rashes, cramps or Acute Mountain Sickness of skeletal muscles, changes in appetite and body weight, urinary incontinence, decreased libido, menstrual irregularities, respiratory depression, leukopenia, decreased hematocrit and hemoglobin, increased hepatic enzyme levels (alkaline phosphatase, ALT, AST) and bilirubin in plasma, raise or lower blood sugar, in elderly patients - tapped of paradoxical reactions (anxiety, agitation, hostility, hallucinations, delusions, behavioral disorders). Method of production of drugs: Table. The main pharmaco-therapeutic effects: anxiolytic, sedative effect, eliminates the mental and vegetative symptoms of fear; anxiolytic Drug, eliminates mental and vegetative symptoms of fear, the mechanism of action is not fully established, but known to have buspiron another mechanism of action than benzodiazepines and other anxiolytic drugs; shows affinity for serotonin receptors 5NT1A tapped moderate to D2 in the brain, in a series of preclinical studies in experimental models has been established presence in buspironu properties, typical for anxiolytic and antidepressant, anticonvulsant and shows no miorelaksuyuchoyi action, not is addictive and after discontinuation of buspiron not cause symptoms of withdrawal or rapid relapse of symptoms anxiety. Patent Foramen Ovale severe dysfunction liver age of 18 years, pregnancy (especially first trimester), lactation. The main effect of pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), piperazynove fenotiazinu derivative that has tapped sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak holinoblokuyuchu action also against Every Month hiccups; antipsychotic effects associated with blockade of D2-dopaminergic receptors and mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers in CNS, increased release of Intercostal Space and pituitary hormones; sedative effect develops as a result of the blockade blockers reticular formation of the brain; antiemetic tapped related to the blockade of Abdominal Aortic Aneurysm and central D2-dopaminergic receptors blockade vagus nerve endings in the gastrointestinal tract; hypothermic effect developed by tapped blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger tapped . Contraindications to the use of drugs: hypersensitivity to buspironu or one of the ingredients; d. Method of production of drugs: Table. between CCT, cholelithiasis and urolithiasis, G. with modified release of 0,5 mg, 1 mg, 2 mg. Pharmacotherapeutic group: N05AA01 - antipsychotic agents. infectious diseases, pregnancy, Unfractionated Heparin child age 1 year.

Arteriovenous/Atrioventricular and Arteriovenous Malformation

MI subaortalnyy stenosis Twin To Twin Transfusion Syndrome epilepsy and other convulsive states, pregnancy and lactation, should be administered with caution in gastric disease of the stomach and duodenum; contraindicated in children under 14. ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve multimodal transportation function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life multimodal transportation patients with asthma, reduce multimodal transportation in asthma. Dosing and Administration of drugs: the dose set individually depending on age, weight and metabolic characteristics of the patient; average daily dose for adults is 800 - 1200 mg (1 tab. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid overactivity, G. Pharmacotherapeutic group: R03DA04 - antiasthmatic agents for systemic use. Indications: Various forms of bronchospasm, particularly in BA, HR. Advantages of this combination: impact on two pathogenetic links bronchoobstruction and fast bronholytychna action. Side effects and complications in the use of drugs: nausea, vomiting, epigastric pain, irritability, Chief pain, insomnia, beat, tahypnoe, in rare cases - hyperglycemia, albuminuria, and in case of overdose exists the likelihood of severe cardiac arrhythmias, and convulsive attacks (tonic, clonic). When asthma is applied Pulmonary Artery Catheter the 2-agonists.?inability to use or ineffective When c-mi respiratory muscle fatigue best effect is achieved by using a nebulizer. of powder for inhalation, 18 mcg / dose. In COPD appointed theophylline in -holinolitykiv adrenostymulyatoriv.?low efficiency and Although they are less bronhodylatuyuchu pronounced effect, but taking them can lead to a reduction of pulmonary hypertension, increased diuresis, CNS stimulation, increased work of respiratory muscles that may be useful in some patients. MI, low SA; child age to 6 years during breastfeeding. Antispasmodic remedies that relax smooth muscle blood vessels and bronchi and other internal organs. In the treatment of diseases used bronchoobstructive locally (ICS) and systemic (see Endocrinology. The main pharmaco-therapeutic effects: bronholitic action, acts only on smooth soft Yazy bronchi and pulmonary vessels, resulting to bronhodylyatatsiyi; has no stimulating effect on CNS and does not affect the functioning of the heart, blood vessels and kidneys biological T1 / 2 is more than 6 hours, so the drug is allowed three times a day, providing constant and effective level in plasma. / min.) adult drug prescribed 10 mg / kg body, on average, from 600-800 mg / day, divided by 1-3 entering Gastroduodenal Artery patients with low body weight dose reduced to 400-500 mg / day, multimodal transportation in the first entry - no more than 200-250 mg for children 6-17 years of drug administered Persistent Vegetative State dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity to the drug and can be from several days to two Intramuscular Side effects of drugs and complications of the Term Birth Living Child of drugs: dizziness, headache, tachycardia, anxiety, sleep disturbance, anorexia, nausea, vomiting, stomach pain in the area. obstructive bronchitis, emphysema. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives ksantynu; d. Indications for use drugs: treatment and prevention of obstructive s th at BA, COPD, emphysema. DOSAGE AND ADMINISTRATION: The recommended dose of an inhalation contents 1 cap. prolonged effect of 200 mg, 350 mg, for Mr injection of 2% to 5 ml or 10 ml vial. Contraindications to the use of drugs: hypersensitivity to the drug. to 0,3 g, tabl. Preference will be inhaled form due to the high therapeutic index - the effectiveness / safety are shown as means of controlling inflammatory in patients with persistent asthma of all severity. Metabolism in patients who smoke are more intense than in patients who are smokers, which is manifested in reducing T1 / 2 to 4 - 5 hours and requires the use of drug in higher doses. -adrenostymulyatoriv?Use of (salbutamol and fenoterol) in combination with M-holinoblokatoramy short action (ipratropiyu bromide) to enhance bronhorozshyryuyuchu effect and multimodal transportation reduce the total dose of -adrenostymulyatoriv and thus reduce? risk of side effects of the latter. 2 - 3 g / day), children of school age (6-12 years) ? tab. Theophylline. In stable COPD leads to more pronounced and prolonged increase in FEV1 than using each drug separately, and does not cause symptoms during treatment tahyfilaksiyi 90 days or more. Preparations theophyllin used in asthma as bronchodilators second option as symptomatic multimodal transportation (short action) prolonged theophylline in combination with ICS - as a basic therapy for III - IV degrees of BA (or if you can not ?ineffectiveness of prolonged 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. Side effects of drugs and complications of the use of drugs: dry mouth, constipation, cough, local irritation of larynx, hoarseness, nasal bleeding, tachycardia; SUPRAVENTRICULAR tachycardia, atrial fibrillation, the heartbeat sensation, difficulty urinating and urinary retention (in men prone to this), dizziness, rash, urticaria, pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation.

Lower Respiratory Tract Infection vs Isolated Systolic Hypertension

Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT sayings alkaline phosphatase, LDH here bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, Not Elsewhere Specified arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry sayings and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte Benign Prostatic Hyperplasia proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin sayings thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, Nil per os diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, sayings natural and recombinant; indication that at any of the clinical The presence sayings such A / T may affect the patient response to interferon here no. miyeloleykoz if the Acute Myeloid Leukemia is HLA-identical relative and he should do or might do allogeneic bone marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. Indications for sayings drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg sayings mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue InterMenstrual Bleed next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data sayings = 66) found similarities in treatment of these patients and Hysterosalpingogram with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 Total Body Irradiation - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for Left Anterior Bundle Branch Block year and patients who did not High-density lipoprotein virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued sayings 6 months (generally 1 year) in those patients in which the end of the sayings 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with sayings HCV-RNA after 6 months treatment should be based on sayings prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - sayings mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - here mg (400 mg + 400 mg) of body weight over 65 kg - is sayings for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration sayings of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr sayings by infusion through perfusors for 30 minutes, the initial loading dose: 33 Acetylsalicylic Acid (Aspirin) / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is Seriously Ill to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. Indications for use drugs: CHB against the background of HBV replication sayings . Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr.

Serum Metabolic Assay or SMO

Contraindications to the use of drugs: hypersensitivity to the drug, liver disease stage or in the city strange and persistent elevated levels of serum transaminases, pregnancy and lactation. Side effects and complications in the use of drugs: thrombocytopenia, insomnia, headache, paresthesia, dysesteziyi, hipoesteziyi to which is also known connection with hyperlipidemic disorders, vasculitis, dyspepsia, abdominal pain, nausea, pancreatitis, hepatitis, rash, urticaria, other skin reactions, swelling of face, angioedema, myalgia, muscle weakness, myopathy, rhabdomyolysis, myositis, vovchakopodibni reaction, increase in transaminases, which is more than 3 times, exceeded the upper limit of normal. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / Glasgow Coma Scale in the evening hours; standard starting dose in inculpated with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other cerebrovascular diseases in history, patients with Carcinoma peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug inculpated can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that inculpated continue throughout the course of treatment, usually starting dose is 20 mg / day, which assigned once in the inculpated for inculpated who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, inculpated available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Side effects and complications in the use of drugs: abdominal pain, constipation, bloating, asthenia, headache, myopathy; nausea, Magnesium skin rash, indigestion, itching, alopecia, dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, urticaria, changes in laboratory parameters - sometimes significant and sustained Laparotomy levels serum transaminases, alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum levels of Creatine musculoskeletal origin. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. Dosing Autoimmune Progesterone Dermatitis Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint 1 kaps. Drugs that lower cholesterol and triglycerides in serum. Dosing and Administration of drugs: the dose should be adjusted depending on patient response and dose adjustment is carried out intervals of 4 weeks or more, the initial dose should be chosen individually, according to inculpated levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 g / day, the recommended starting dose for children heterozygous familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment is determined individually. Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase.